The agency has set a PDUFA action date of December 16th. I am really excited to take over this task and indeed a number of reasons for that. In addition, also with a rather limited or impacted destocking on the base business for PS, we also see a margin impact on that, especially, as I mentioned before, in the second quarter, and that it will gradually kind of come up again as we see the inflection point for the destocking. But we gave you some, if you will, book ends. We will now go to your next question. We have narrowed the estimated range of operating expenses to be between $23.3 billion and $24.1 billion. Innovation Merck's Q3 2022 earnings report October 27, 2022 Share this article Merck's ( NYSE: MRK) Q3 2022 results reflect sustained strong business momentum across key growth drivers as well as investment and progress in the pipeline. Thank you. And a number of dampening effects on the EBITDA pre margin, such as adverse mix effects, a higher operating expense base for our ongoing strategic investments, as well as reduced operating leverage will only start to become more visible during the course of 2023. The strength of the data from the Phase 3 STELLAR trial studying sotatercept in pulmonary arterial hypertension reinforces our belief in this important new mechanisms potential to change the treatment paradigm for patients. On LAGEVRIO, we continue to prioritize global access during surges of COVID-19 around the world, including in Japan, where the Ministry of Health Labor and Welfare recently granted full approval for the treatment of COVID-19. So we see a recovery here for the second half in our model. The FDA has granted this combination Breakthrough Therapy Designation and the European Medicines Agency has awarded PRIME designation for high-risk stage III and IV melanoma following complete resection. We all deal with, and I mean -- look, I mean, we have absolutely regular intensive conversation with customers and also for their benefit, right, because to serve them well once they reach the inflection point. Q4 2023 Press Conference and Webcast for Analysts. Thanks a lot. Could you talk to the planned cardiovascular outcome trial for your oral PCSK9, in particular, how you balance some of the historic data supporting the idea that in trial treatment duration is closely tied to efficacy and the parenterals were probably dosed for too short a time suggesting that you need to have a longer trial versus, on the other hand, the impact of the IRA contending returns at least in the Medicare population in the U.S.? When do you expect to be able to start retaking share in China or [technical difficulty] going forward due to local competition? Good afternoon. So you have to understand that we are not disclosing a specific target of business, but we are -- this is giving you a frame on the scope in which we are operating and scouting. Outside the U.S., we continue to expect strong volume growth for KEYTRUDA; however, pricing is an increasing headwind, particularly as we launch new indications in key European markets, which will temper ex-U.S. growth. I probably want to just focus really on the Phase 3s that we're advancing in melanoma and likely in others. Overall, we had a solid start to 2023 in a challenging business environment supported by our multi-industry setup. Please note, mark your calendars, that we will be hosting our Capital Markets Day on October 19 here at our headquarters in Darmstadt. And compared with our previous quarters of the minus 1 to minus 4 for sales and EBITDA pre, this is a slightly higher negative effect mainly due to some somewhat weaker USD and weakening ASEAN currencies such as the ones I mentioned already, the Japanese yen and the Chinese renminbi. Lenvima alliance revenue grew 5% due to increased uptake in the treatment of certain patients with advanced renal cell carcinoma in key European markets. That was very much something the industry pushed for, and we feel good about. Peter, yes, on your questions related to the margin, so there are a couple of effects. Webcast 4Q22 Merck Earnings Presentation 4Q22 Merck Earnings Announcement 4Q22 Merck Other Financial Disclosures Transcript Form 10-K So those are the balances. I'll just answer by the competitive dynamics make us more enthusiastic to push our programs harder and faster. And so we believe that giving other routes of administration will be important. Maybe could you elaborate a bit on how do you see the recovery and when is it a slow recovery or still some pressure in the short-term? Dean, on TIGIT, we know the doublet arm was not going to meet the PFS. Our SEC filings, including Item 1A and the 2022 10-K, identify certain risk factors and cautionary statements that could cause the company's actual results to differ materially from those projected in any of our forward-looking statements made this morning. Yes. Our N&I franchise was down slightly 2% organically with a strong Mavenclad performance of 23%, largely offsetting an amplified 25% Rebif decline in the quarter. Our vaccines portfolio delivered excellent growth led by GARDASIL, which grew 43% to $2 billion. You and your partner Moderna are conducting a Phase 1 basket trial of the PCV. Welcome to Merck's First Quarter 2023 Conference Call. For Electronics, we forecast an organic sales development of minus 2 to plus 3, moderating our previous qualitative guidance range. Thank you. And our ability to recruit and do an important trial there is also important. We've had very mixed commentary from peers on near-term trends. I have two questions on Life Science, please. So concerning visibility for the second half, so maybe three factors I would like to emphasize. In Electronics, our semi business was up 2% in the quarter, significantly outperforming a declining market. PRA023 Phase 2 results in both Ulcerative Colitis and Crohn's disease demonstrated strong efficacy. Merck & Co., Inc. (NYSE:NYSE:MRK) Q1 2023 Earnings Conference Call April 27, 2023 9:00 AM ETCompany ParticipantsPeter Dannenbaum - Vice President, Investor RelationsRobert Davis -. We will continue to execute a modest level of share repurchases this year. And importantly, we look forward to meeting many of you in person at the upcoming road show meetings as we continue to update you also in the future as the year progresses. We will be providing data from the data that we have in a series of cancers at ASCO on June 5th. No login or account required. At the American Association for Cancer Research annual meeting, in collaboration with Moderna, we announced detailed results from KEYNOTE-942, a Phase 2b study evaluating KEYTRUDA in combination with V940 also known as mRNA-4157, an individualized neoantigen therapy, for the adjuvant treatment of stage III and IV melanoma in patients with high risk of disease recurrence following complete resection. Thank you very much. We also look forward to providing a new treatment option to certain adult patients with bladder cancer following the recent approval of KEYNOTE-869. And then finally, I just want to add, I want to wish Marcus well in his new endeavors. The increase was driven by higher adjusted . As you know, the challenge here is that the overall screening rates are lower. Ladies and gentlemen, thank you for your attendance. Obviously, that's a look into the future. Q3 2023 Press Conference and Webcast for Analysts. Q1 2024 Press Conference and Webcast for Analysts. These results reinforce our confidence in the robust demand for our innovative portfolio and in our outlook for the remainder of 2023, which Caroline will speak to in a moment. DS&S, as you mentioned, we will have some project phasing benefit in Q4. So typically, of course, we do not comment on competitors and their moves, but just from the public sources. Now moving into Slide #17, I will give additional color by business sector. Few quick ones. I would just focus on the pulmonary artery hypertension. Please disable your ad-blocker and refresh. And now I will turn the call back to Peter. So you have the classical exclusion criteria. And I think the aperture of being able to do it in the lung is going to be substantial. So by extension, the triplet may have a shot at meeting PFS. Welcome to Merck's third quarter 2021 conference call. Robert M. Davis Chief Executive Officer and President. Your line is open. That is the -- it refers to the so-called KMG business that was acquired by Entegris with the Cabot acquisition, and it was plan to be disposed of any time and now it happened. To ensure this doesnt happen in the future, please enable Javascript and cookies in your browser. Importantly, it also reinforces the need for early detection through lung cancer screening. At the same time, I would like to highlight again what I said before given the rather smaller base, especially in the CDMO business, we see more fluctuations, right? You may disconnect. Merck Makes a Bold Move That Could Transform Its Business. And I guess also, I guess the read-through would be also to how potential business development as well? We are proud of the progress we are making and look forward to hosting an investor event at ASCO in Chicago. We're actually seeing good uptake. So to paint the picture, obviously, we saw that trend during -- in the course of Q1 has a more stronger pattern. Is it more just about the impact of destocking now being felt in process or pressures from weaker buyer activity? Excluding the COVID impact, we forecast organic sales growth of plus 3% to 8% in the core business. And after that we are happy to take all your questions in our Q&A. And after that we are happy to take all your questions in our Q&A. Although I will tell you, we continue to not believe that going after commercialized assets just for the sake of revenue is not our strategy. Merck (NYSE: MRK) Q1 2023 Earnings Call Apr 27, 2023, 9:00 a.m. Falko, that's obviously a great question. So you mentioned that in the next quarters, the base effect might help, but that just is momentum. Alliance revenue grew 8%, primarily due to increased demand in key European markets in certain patients with ovarian cancer. Peter Dannenbaum. Organic EBITDA pre was up 10.5% in Q1, driven by operating leverage, mix and low comps on gross profit. The Agency has set a PDUFA action date of October 16th and detailed findings will be presented at ASCO in June. results to differ materially from those projected in any of our forward-looking statements made this morning. We will come back to giving you more details on the assumptions later in the presentation. So we're very comfortable moving our IO-IO strategies in earlier stages. We will now go to your next question. I'm sure we're going to hear a lot about evobrutinib on the call. A very high portion of that growth currently is coming from price and our ability to pass on high inflation cost to the end customer. Speaking on today's call will be Rob Davis, our Chief Executive Officer; Frank Clyburn, President of Human Health; Caroline Litchfield, Chief Financial Officer; and Dr. Dean Li, President of Merck Research Labs. We are more dependent on individual batch phasing, and we saw that as a positive effect in the first quarter. Cash out for investing activities increased, primarily driven by higher CapEx to support our growth ambitions. And your next question comes from the line of Simon Baker from Redburn. Next question, please. Obviously, the Bavencio repatriation will have a significant impact as of July 1. And Luisa, I might just add from a commercial perspective, the early stage launch and lung with KEYNOTE-091 is off to a good start. The second point I would just emphasize is there is an evolving view that I think the field is coming to grips with. And of course, the upper end of the scenario would be there's a much stronger -- I wouldn't expect an early inflection point, but probably a steeper inflection point during Q3. But I do -- I would echo your point of view, which is one doesn't want to go too short that one risks the full maximum impact that you can have on the label. So our M&A approach have not significantly changed from what we have already told you during the Capital Markets Day and in other quarterly discussions, that we are operating under the same principle. Now Merck's former executive chairman, he recently shared how his experience growing up during the Civil Rights Movement shaped his career, how he ensured that . I would also remind you that, of course, the EGFR mutation in MET -- with MET amp, the fact that we will not pursue this indication will not change our midterm guidance for Healthcare. Other assets increased due to the mentioned short-term investments and so cash and cash equivalents declined. Please go ahead. The core business was up at a robust 7%, while COVID-related sales continued to decline and has a dampening effect of minus 6% on organic growth. So the GSA contract from your Chinese distributor published a couple of months ago shows really big purchase orders consistently for the next few years and it kind of trails off and declines. And it's a rather low margin business where I think it's not in any competition to our portfolio. And question is now how well are these additional requirements are already embedded into the market forecast, which is still very steep. We've obviously got questions about EVO safety. Experts believe that the biological mechanism driving long-term disability are not really relapses of focal RMI activity but rather smoldering inflammation leading then later to disability accumulation over time. I think you're referring to the fact that there is a view that if those studies with the antibodies had gone out a little bit longer, that they would have had a more profound impact in terms of outcomes. So I would not interpret that as implying a decline in GARDASIL in China over the coming years. But as we sit here today, the launch is going well. So that is a kind of a onetime effect during Q1. We are working diligently to submit filings from the STELLAR data to regulatory agencies and at this time, anticipate filing in the U.S. in the third quarter of this year followed by the EU. So I just wonder how once we get beyond the initial cyclical challenges at the moment, how that has changed your long-term outlook for demand? Transcript : Merck & Co., Inc., Q3 2022 Earnings Call, Oct 27, 2022 October 27, 2022 at 08:00 am . Merck KGaA (OTCPK:MKGAF) Q1 2023 Earnings Conference Call May 11, 2023 8:00 AM ET, Constantin Fest - Head of Investor Relations, Beln Garijo - Chair of the Executive Board and Chief Executive Officer, Peter Guenter - Chief Executive Officer, Healthcare, Matthias Heinzel - Chief Executive Officer, Life Science, Kai Beckmann - Chief Executive Officer, Electronics, Helene von Roeder - Chief Financial Officer. And we will take full control of the global commercialization effect of June 30. But obviously, we've got to get that going to do that in the adjuvant setting. And what's your expectations for this opportunity? This call has been concluded. And as such, I'm looking forward to share my experience here as well. Capital Markets Day 2023. Thank you very much, Sharon. Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. And with that, let me hand back to Beln for the outlook. And as you said, there is a renewed interest given the recent transaction, and I don't know if Caroline, would you like to answer that? And the next question comes from the line of Gary Steventon, BNP Paribas. We just have to make sure it's sustainable from a business perspective. On the biotech funding, look, just to size it, overall, Life Science is less than 10%, if you will, exposed to the early smaller biotechs. During the call, company executives will provide an overview of Merck's performance for the quarter. We mentioned before that we're expanding our footprint in PS in Wuxi, and we are continuing to drive that capacity because it is really crucial to then kind of serve the customers locally from within the country for the country. You've talked in the past about OLED offsetting LCD and getting display stabilized. SLS was running rather strongly, and we continue to expect that. For sotatercept, certainly, a broad scope of potential not just from the stellar results, but in earlier and later line, you have HYPERION and ZENITH. If it brings with it a commercial opportunity, great, but it always will have to have a pipeline element for us to want to go there. That is, by the way, the reason why the margin impact for Life Science is turning from positive to slightly negative now in the most -- so in today's quantitative guidance because the U.S. dollar expectations have not changed. Furthermore, we are excited by the potential to bring an additional treatment option to patients following the positive results of the KEYNOTE-671 study. Last, and this was also hotly debated at AAN, there is an emerging thinking that the concept of MS as one disease is kind of starting to emerge. Contents: Prepared Remarks; Questions and Answers; Call Participants; Prepared Remarks: Operator . Yes. We'll have an investor, but it will also be in the ASCO, I believe, already accepted for presentation there as well. PRA023's Phase 2 results in both ulcerative colitis and Crohns Disease demonstrated strong efficacy. Yes. And on that basis, of course, visibility is not that long that we have into the market since we depend on the decisions, on wafer start decisions of our customers. Please go ahead, sir. Overall Q1 has once again illustrated the strength of our business in a year that we have deemed to be transitional. At the bottom line, as shown on slide 23, second quarter 2023 adjusted earnings per share was $0.60, as compared to $0.48 for the year ago period. So we certainly also saw there a similar effect, like I mentioned before, around the destocking, especially in PS. first minutes of the call we would like to spend by guiding you through the key slides of this presentation. Next question, please. So as we sit here today, we continue to see this as a meaningful opportunity and long term will continue to drive growth for us in long. We also announced that the FDA has accepted our application for KEYTRUDA in combination with chemotherapy for the first-line treatment of patients with HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma. The remainder of my revenue comments will be on an ex exchange basis. So did you gain share? Please go ahead. And is there any additional color there, would be helpful, in terms of framing the areas where you're seeing more pressure and if there's any offsets in the mix as well. I'm very encouraged by the substantial progress we've made across our broad pipeline. Also for your information, the first minutes of the call we would like to spend by guiding you through the key slides of this presentation. This is really the first time that I can recall seeing the impact of a personalized or individualized neoantigen therapy or a personalized cancer vaccine that has that profound of a readout in a Phase 2. I would like to remind you that some of the statements that we make today may be considered forward-looking statements within the meaning of the safe harbor provision of the U.S. 29. Welcome to Merck's Second Quarter 2021 Conference Call. We continue to assume a full year tax rate between 17% and 18% and approximately 2.55 billion shares outstanding. We also believe that it will potentially reshape how people think about the treatment of PAH largely people thought about vasodilation or dilation. So I have to say I was a bit surprised of the question that was raised around the announcement because several of you asked, why are we [technical difficulty] this news from today's earnings release announcement? Dean, just hoping if you could update us, I believe, previously, it was stated that we may see some longer-term data later this year. Can you elaborate on the design of the trial? Pretty strong growth in the first quarter. In our hospital acute care portfolio, BRIDION sales grew 27%, driven by an increase in market share among neuromuscular blockade reversal agents. In North America, Q4 revenue grew 5%, Nike Direct was up 15%, and Nike Digital grew 17%. So when you're thinking about the progress that you guys have had in internal pipeline and then now you have the Prometheus deal, is there a priority or a bias when you consider business development from either early or later stage deals or from therapeutic areas, oncology, CV or maybe some emerging therapeutic areas in your portfolio? And then a second question for Kai. Second, we confirm our organic growth targets at group level for the year 2023, despite operating in an increasingly challenging environment that we have extensively discussed during the call. Welcome to the Merck & Company Q1 Sales and Earnings Conference Call. And maybe if you could just help us understand your enthusiasm for that particular product and where you feel it would be likely differentiated from other products in the category? Moving on to Healthcare. Thank you. On the liability side, we have seen stable provisions for employee benefits as the interest rates have not significantly moved since year-end.